%0 Journal Article
%T A Study on Pre-Induction Cervical Ripening with PGE2 Vaginal Tablet One (3 mg) vs. Half (1.5 mg) in Low Risk Multi Parous Mothers at 40 Weeks of Gestation
%A Naleen Ratnayake
%A Ahangama Arachchige Nilanga Nishad
%A Yahampath Arachchige Gamini Perera
%A Devasuriya Pathinayakalage Lanka Rasanjana
%A Samarakoon Mudiyanselage Sameera Gayanath Gunarathna
%A Prabath Kularathna Abeysundara
%J Open Journal of Obstetrics and Gynecology
%P 1005-1012
%@ 2160-8806
%D 2021
%I Scientific Research Publishing
%R 10.4236/ojog.2021.118094
%X Backgrounds: Induction of labor is a common practice. In women with </span><span style=\"font-family:Verdana;\">immature</span><span style=\"font-family:Verdana;\"> cervix, PGE2 is commonly used for
pre-induction. We hypothesized that PGE2 1.5</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg may be equally effective to PGE2 3</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg in multiparous women for labor induction. The
present effort was an attempt to compare the efficacy and effects of
pre-induction cervical ripening with PGE2 3</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg vs</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">.</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"> 1.5</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">mg in multi-parous mothers (2nd and 3rd Pregnancy)
at 40 weeks.</span></span></span></span><span><span><span><span style=\"font-family:&quot;\"> </span></span></span></span><span><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">Methods: A </span><span style=\"font-family:Verdana;\">double</span></span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">-</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">blind</span></span></span></span><span><span><span><span
%K Pregnancies
%K PGE2
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=111315